Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to, potential market sizes and market share, ACIP recommendation impact market trends, growth perspective, and rates, manufacturing plans, seasonality, financial guidance, and trends, including revenue, profitability and efficiency of current capitalization timing and results of clinical trial starts and data readouts and potential future uses of CpG 1018 adjuvant. Joining me on the call today are: Ryan Spencer, chief executive officer; Donn Casale, senior vice president of commercial; Rob Janssen, chief medical officer; and Kelly MacDonald, chief financial officer.